O11 biomedical
June 24, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Respiratory
At O11 biomedical, we will improve the lives of millions of patients suffering from the progressive lung disease COPD:
We allow breathing via the gut!
Our first in-class oral drug, RESPILIQ, binds CO2 during gut passage.
RESPILIQ treats severe COPD with minimal patient burden, expected high compliance, and minimal side effects.
We expect to start our FiH study in Q1 2027.
Company HQ City:
Aachen
Company HQ State:
NRW
Company HQ Country:
Germany
Year Founded:
2022
CEO
Richard Ramakers
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}